CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-05 | PAKOLA STEVE Chief Medical Officer | Option exercise · Stock Options (Right to Buy) 10b5-1 | −12,878 | 31,277 | ||
| 2024-02-14 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +15,000 | $3.76 | $56K | 423,035 |
| 2024-02-14 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −4,652 | $16.47 | $77K | 418,383 |
| 2024-02-14 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −10,348 | $16.88 | $175K | 408,035 |
| 2024-02-14 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −15,000 | 126,354 | ||
| 2024-01-16 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +45,000 | $3.76 | $169K | 453,035 |
| 2024-01-16 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −45,000 | $15.18 | $683K | 408,035 |
| 2024-01-16 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −45,000 | 141,354 | ||
| 2024-01-03 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 | −17,237 | $17.39 | $300K | 107,192 |
| 2024-01-02 | Simpson Curran Chief Oper. & Tech. Officer | Shares withheld for taxes | −8,120 | $17.95 | $146K | 84,865 |
| 2024-01-02 | Simpson Curran Chief Oper. & Tech. Officer | Grant or award | +38,462 | 123,327 | ||
| 2024-01-02 | Simpson Curran Chief Oper. & Tech. Officer | Grant or award · Stock Options (Right to buy) | +61,050 | 61,050 | ||
| 2024-01-02 | PAKOLA STEVE Chief Medical Officer | Shares withheld for taxes 10b5-1 | −10,385 | $17.95 | $186K | 92,378 |
| 2024-01-02 | PAKOLA STEVE Chief Medical Officer | Grant or award 10b5-1 | +32,051 | 124,429 | ||
| 2024-01-02 | PAKOLA STEVE Chief Medical Officer | Grant or award · Stock Options (Right to buy) 10b5-1 | +50,875 | 50,875 | ||
| 2024-01-02 | Danos Olivier Chief Scientific Officer | Shares withheld for taxes | −8,410 | $17.95 | $151K | 86,391 |
| 2024-01-02 | Danos Olivier Chief Scientific Officer | Grant or award | +38,462 | 124,853 | ||
| 2024-01-02 | Danos Olivier Chief Scientific Officer | Grant or award · Stock Options (Right to buy) | +61,050 | 61,050 | ||
| 2024-01-02 | Vasista Vittal Chief Financial Officer | Shares withheld for taxes | −4,534 | $17.95 | $81K | 210,467 |
| 2024-01-02 | Vasista Vittal Chief Financial Officer | Grant or award | +16,026 | 226,493 |
Page 10 of 11 · 216 trades